Article
Behavioral Sciences
Mary Seeman
Summary: The review examines the potential role of intestinal organisms in response/non-response to antipsychotics, highlighting that current research in this area is mostly theoretical but showing increasing evidence from animal experiments and clinical trials on the impact of gut bacteria on drug response.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Farhana Islam, Xiaoyu Men, Kazunari Yoshida, Clement C. Zai, Daniel J. Mueller
Summary: Pharmacogenetics research has shown that genetic factors influence the efficacy and tolerability of antipsychotic treatment, with the most robust findings related to associations between polymorphisms in CYP2D6 and exposure and response to specific antipsychotics. Product labels and guidelines have provided dosing recommendations based on CYP2D6 metabolizer phenotypes.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Psychiatry
Elmars Rancans, Zsofia Borbala Dombi, Agota Barabassy
Summary: This perspective paper aims to shed light on the appropriate dosing strategies of cariprazine, a novel antipsychotic medication, through summarizing clinical data and real-world evidence.
FRONTIERS IN PSYCHIATRY
(2022)
Review
Psychiatry
Helene Verdoux, Aude Sibert, Clelia Quiles
Summary: This review explored the association between trauma exposure and poorer response to antipsychotic treatment in schizophrenia patients, finding a link between trauma and non-remission of symptoms or treatment-resistant schizophrenia. Although evidence supporting this link is limited, trauma history should be systematically investigated in all TRS patients.
PSYCHIATRY RESEARCH
(2022)
Article
Health Care Sciences & Services
Gesche Jurgens, Benjamin Skov Kaas-Hansen, Merete Nordentoft, Thomas Werge, Stig Ejdrup Andersen
Summary: This study found an association between genetically predicted CYP2D6 metabolic capacity and antipsychotic-induced weight gain. The results showed significant weight gain in both CYP2D6 poor metabolizers and ultrarapid metabolizers after taking antipsychotic drugs.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Nanfu Deng, Niharika Mallepally, Frederick B. Peng, Aleem Kanji, Marco Marcelli, Ruben Hernaez
Summary: Low serum testosterone is associated with increased morbidity and mortality in cirrhosis patients. Testosterone supplementation improved intermediate endpoints, but there was no conclusive data on clinical outcomes.
LIVER INTERNATIONAL
(2021)
Article
Psychiatry
Johannes Lieslehto, Jari Tiihonen, Markku Lahteenvuo, Antti Tanskanen, Heidi Taipale
Summary: It remains unclear what factors contribute to primary nonadherence to antipsychotic treatment. This study found that young age, concomitant medication use, substance abuse, previous suicide attempts, and certain medical conditions are associated with primary nonadherence. Patients using clozapine and long-acting injectables demonstrate higher adherence to treatment compared to oral agents.
SCHIZOPHRENIA BULLETIN
(2022)
Review
Cell Biology
D. Kavindi Weerasinghe, Jason M. Hodge, Julie A. Pasco, Rasika M. Samarasinghe, Behnaz Azimi Manavi, Lana J. Williams
Summary: This article provides an overview of the mechanisms of action of antipsychotics and the expression profiles of dopamine, serotonin, and adrenergic receptors during osteoclastogenesis and osteoblastogenesis, aiming to elucidate the effects of antipsychotic use on bone.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Multidisciplinary Sciences
Behnaz Azimi Manavi, Amanda L. Stuart, Julie A. Pasco, Jason M. Hodge, D. Kavindi Weerasinghe, Rasika M. Samarasinghe, Lana J. Williams
Summary: Antipsychotic use is associated with an increased risk of fracture, particularly in men and women. Regular monitoring of bone health is suggested for individuals using antipsychotic medications.
SCIENTIFIC REPORTS
(2023)
Article
Psychology, Multidisciplinary
Luiza Grycuk, Francesca Moruzzi, Elena Bardjesteh, Fiona Gaughran, Iain C. Campbell, Ulrike Schmidt
Summary: The study provides insights into the perceptions and experiences of individuals with schizophrenia regarding transcranial direct current stimulation (tDCS). Participants were concerned about the safety of tDCS, but educational materials and a good relationship with the researcher helped alleviate their fears. Although participants found tDCS uncomfortable, they agreed that the unpleasant sensations were short-lived and did not cause long-term anxiety.
FRONTIERS IN PSYCHOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Piotr Stepnicki, Olga Wronikowska-Denysiuk, Agata Zieba, Katarzyna M. Targowska-Duda, Agata Bartyzel, Martyna Z. Wrobel, Tomasz M. Wrobel, Klaudia Szalaj, Andrzej Chodkowski, Karolina Mirecka, Barbara Budzynska, Emilia Fornal, Jadwiga Turlo, Marian Castro, Agnieszka A. Kaczor
Summary: The study aims to find new antipsychotics by optimizing the compound D2AAK3, a multi-target ligand of G-protein-coupled receptors (GPCRs). Compounds 1 and 10 were selected based on their receptor profile and evaluated for their antipsychotic activity, as well as their effects on memory and anxiety processes. Molecular modelling and X-ray study were conducted to investigate the interactions and stable conformation of the compounds.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
(2023)
Article
Neurosciences
Thomas A. Pollak, Angela Vincent, Conrad Iyegbe, Ester Coutinho, Leslie Jacobson, Dan Rujescu, James Stone, Julie Jezequel, Veronique Rogemond, Stephane Jamain, Laurent Groc, Anthony David, Alice Egerton, Rene S. Kahn, Jerome Honnorat, Paola Dazzan, Marion Leboyer, Philip McGuire
Summary: In patients with first-episode psychosis, the presence of NMDAR antibodies does not indicate a need for immunotherapy instead of antipsychotic medications. Further studies are needed to determine the proportion of FEP patients who are NMDAR antibody positive and may benefit from immunotherapy based on coexisting cerebrospinal fluid inflammatory changes or other paraclinical evidence.
BIOLOGICAL PSYCHIATRY
(2021)
Article
Multidisciplinary Sciences
Elias D. Mouchlianitis, Lucy D. Vanes, Derek K. Tracy, Anne-Katherin Fett, Daniel Joyce, Sukhi S. Shergill
Summary: Glutamatergic dysfunction is associated with treatment resistance in individuals with schizophrenia. This study used neurochemical and functional brain imaging methods to investigate glutamatergic dysfunction and reward processing in treatment-resistant and treatment-responsive schizophrenia. The results suggest that glutamatergic differences can differentiate treatment-resistant and treatment-responsive schizophrenia, which has potential diagnostic value.
SCIENTIFIC REPORTS
(2023)
Article
Health Care Sciences & Services
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Anastasiia A. Goncharova, Arkadiy Semke, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: Metabolic syndrome (MetS) is a common complication of schizophrenia that is exacerbated by long-term use of antipsychotics. The study found that levels of leptin were significantly increased in MetS patients, while ghrelin levels were significantly decreased. There were fewer significant correlations between ghrelin and other hormones in MetS patients compared to those without MetS.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Psychiatry
Anna Ceraso, Jessie Jingxia Lin, Johannes Schneider-Thoma, Spyridon Siafis, Stephan Heres, Werner Kissling, John M. Davis, Stefan Leucht
Summary: Antipsychotic drugs are effective in maintaining treatment for schizophrenia, preventing relapse and reducing hospitalization. They also improve quality of life, social functioning, and the possibility and duration of symptom remission. However, antipsychotic drugs may lead to side effects such as movement disorders and weight gain.
SCHIZOPHRENIA BULLETIN
(2022)
